13 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Tongji University
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Pfizer
Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.
Amgen
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
Merck Research Laboratories
Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.
Boehringer Ingelheim Pharmaceuticals
Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.
Boehringer Ingelheim Pharmaceuticals
Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Boehringer Ingelheim Pharmaceuticals
Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.
Universite Paris 5 René
Inhibition of cytochrome P450 monooxygenase-catalyzed oxylipin formation by flavonoids: Evaluation of structure-activity relationship towards CYP4F2-selective inhibitors.
University of Wuppertal
Discovery of new indole-based acylsulfonamide Na
Bristol-Myers Squibb Research and Development
(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.
De Montfort University